妊娠前のオクレリズマブ使用と新生児のB細胞減少:症例報告

Georgios Eleftheriou, Anna Sangiovanni, Raffaella Butera

International journal of clinical pharmacology and therapeutics

|September 4, 2025

まとめ

オクレリズマブは,多発性硬化症 (MS) の患者のB細胞を枯渇させる. 新生児のB細胞が完全に枯渇した最初の事例です

科学分野:

免疫学
神経学
薬理学について

背景:

オクレリズマブは,再発性多発性硬化症 (MS) に対して承認されたB細胞減少療法です.
過去の研究では,子宮内でのオクレリズマブ曝露で不発症や新生児のB細胞枯渇のリスクは最小限であると示唆されています.
新生児のB細胞数については,妊婦の治療終了後数ヶ月後に妊娠した場合に限られたデータがあります.

研究の目的:

新生児のB細胞が完全に枯渇した最初の症例を報告する
新生児のB細胞数に対するオクレリズマブの影響を調査する.

主な方法:

オクレリズマブで治療されたMSの妊婦の症例報告
出産後の新生児の周辺血液のB細胞数値の分析
オクレリズマブと新生児のアウトカムに関する既存の文献のレビュー.

主要な成果:

新生児は一時的で完全なB細胞減少を示した.
母のオクレリズマブ投与は,受胎の3ヶ月前に終了しました.
この発見は,新生児のB細胞への影響が最小限にあるという以前の報告と対照的です.

結論:

妊娠が遅れた場合でも,オクレリズマブは新生児の深い長期のB細胞減少を引き起こす可能性があります.
長期的影響を理解し,オクレリズマブ治療後の安全な受精を確立するために,さらなる研究が必要である.
このケースは,オクレリズマブで治療を受けた母親から生まれた乳児の注意深いモニタリングの必要性を強調しています.

さらに関連する動画

05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

15.1K

08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

15.9K

関連する概念動画

01:07

Teratogenicity

2.7K

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

2.7K

01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

264

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

264

01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

200

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

200

01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

230

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

230

01:25

Immunodeficiency Diseases

1.2K

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...